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Acute Effects of a Selective Cannabinoid-2 Receptor
Agonist on Neuroinflammation in a Model
of Traumatic Brain Injury
Melanie B. Elliott,1 Ronald F. Tuma,2 Peter S. Amenta,1 Mary F. Barbe,3 and Jack I. Jallo1

Abstract

Proposed therapeutic strategies for attenuating secondary traumatic brain injury (TBI) include modulation of
acute neuroimmune responses. The goal of this study was to examine the acute effects of cannabinoid-2 receptor
(CB2R) modulation on behavioral deficits, cerebral edema, perivascular substance P, and macrophage/microglial activation in a murine model of TBI. Thirty male C57BL/6 mice underwent sham surgery, or cortical
contusion impact injury (CCI). CCI mice received vehicle or the CB2R agonist 0-1966 at 1 and 24 h after injury.
Performance on the rotarod, forelimb cylinder, and open-field tests were evaluated before and at 48 h after sham
or CCI surgery. Cerebral edema was evaluated using the wet-dry weight technique. Immunohistochemical
analysis was used to examine changes in substance P and macrophage/microglia-specific Iba1 protein immunoreactivity. Locomotor performance and exploratory behavior were significantly improved in mice receiving
0-1966 (CB2R agonist) compared to vehicle-treated mice. Significant reductions were found for cerebral edema,
number of perivascular areas of substance P immunoreactivity, and number of activated macrophages/
microglial cells in the injured brains of 0-1966–treated mice compared to vehicle-treated mice. The findings show
that the effects of the CB2R agonist 0-1966 on edema, substance P immunoreactivity, and macrophage/microglial
activation, were associated with recovery of acute motor and exploratory deficits. This study provides evidence
of acute neuroprotective effects derived from selective CB2R activation that may represent an avenue for further
development of novel therapeutic agents in the treatment of TBI.
Key words: controlled cortical impact injury; glial response; inflammation; neurotransmitters; traumatic brain

injury

Introduction

T

he enormity of the problem of traumatic brain injury (TBI) cannot be overstated, as over 1.7 million
Americans are affected annually, with many suffering fatal or
permanently disabling injuries. Unfortunately, despite the
well-known deleterious effects of TBI, medical and surgical
interventions remain limited, and advancements in treatment
have been relatively non-existent. TBI is a broad term that
envelops a dynamic series of overlapping phases. Primary
injury occurs at the time of the insult and is not amenable to
treatment. It does, however, set in motion a complex constellation of cellular and biochemical processes. The end result, secondary injury, evolves over the subsequent hours to
days, and manifests as cerebral edema, increased intracranial

pressure, ischemia, and eventual infarction. Early edema
formation, in the first 72 h after cerebral contusions, contributes to intracranial hypertension and clinical decline or fatality. This time period is a critical window for interrupting
secondary injury mechanisms (Kawamata and Katayama,
2007). Cerebral edema formation is due in part to neurogenic
inflammatory mechanisms in which the release of substance
P, a potent long-lasting vasoactive tachykinin, is believed to
be the predominant mediator (Donkin et al., 2007, 2009).
Substance P antagonists are currently proposed as a therapeutic approach for TBI (Vink and van den Heuvel, 2010).
However, in a rat model of sciatic nerve section, an unfortunate side effect of 2 weeks of treatment with an antagonist
against the key substance P receptor (neurokinin-1) is widespread bone resorption (Kingery et al., 2003). This latter
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finding suggests that other effective therapies need to be explored.
In the wake of TBI, neuroimmune-inflammatory responses
are important for repair and possible regeneration of the injured central nervous system (CNS), but also contribute to
secondary injury cascades that promote continued cellular
destruction. Although the dual role of the inflammatory response to CNS injury has been well-characterized, the optimal
immunomodulation for improving outcome from TBI remains elusive. Microglial cells, the resident macrophages of
the CNS, along with infiltrating macrophages/monocytes
from the circulation, represent the predominant mediators of
secondary injury. When activated, microglia play a key role in
the production of proinflammatory cytokines, phagocytosis,
and antigen presentation, all of which contribute to the development of cerebral edema and exacerbation of TBI. In the
present study we evaluated the effects of modulating the acute
neuroimmune response by selectively targeting receptors for
endogenous cannabinoids found predominantly on macrophage/microglia in the injured brain. Interestingly, injury to
the CNS, including TBI, increases both the release of endogenous cannabinoids (2-AG and anandamide), and expression of
their receptors (Mechoulam and Shohami, 2007; Panikashvili
et al., 2001; van der Stelt et al., 2002). The general consensus is
that the changes in endocannabinoid and receptor expression
in the injured brain are an attempt at self-protection.
Previous studies have described the presence of a specific
receptor, cannabinoid-1 receptor (CB1R), as the receptor
responsible for inducing the psychoactive effects of D9tetrahydrocannabinol (THC). In 1993, Munro and associates
reported a second cannabinoid receptor, cannabinoid-2 receptor (CB2R), in the immune and hematopoietic systems,
which was later found to be expressed by microglia and astrocytes in the brain (Gong et al., 2006; Munro et al., 1993;Van
Sickle et al., 2005). This second receptor has since been shown
to be devoid of psychoactive effects, while possessing potent
immunomodulatory and anti-inflammatory properties. At
rest, microglial expression of CB2R is negligible, however,
activation, as is seen in TBI, leads to an increase in the expression of the receptor. Evidence is emerging that CB2R
activation modulates microglial function, resulting in predominantly anti-inflammatory and neuroprotective effects
after injury. These findings make the endocannabinoid system, particularly CB2R, a potential target for novel therapeutic
agents for the treatment of TBI. Therefore, the main goal of
this study was to examine the acute effects of a CB2R agonist,
0-1966, on behavioral deficits, cerebral edema, perivascular
substance P immunoreactivity, and macrophage/microglial
activation, in a murine model of TBI. Our hypothesis was that
CB2R activation will reduce inflammation and provide a
neuroprotective effect post-TBI.
Methods
Experimental design, animal care, and anesthesia
Prior to initiating any research, the Thomas Jefferson University Institutional Animal Care and Use Committee reviewed
and approved the research protocol, and approved the use of
male C57BL/6 mice from Charles River as experimental animals. Animal care and use was monitored by the University
Animal Care and Use Committee to assure compliance with the
provisions of federal regulations and the National Institutes of
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Health (NIH) Guide for the Care and Use of Laboratory Animals. All
animals were housed in the Thomas Jefferson University Laboratory Animal Services Facility, which is accredited by the
American Association for the Accreditation of Laboratory
Animal Care, and complies with NIH standards.
The animals were deeply sedated with isoflurane
throughout the surgical procedures and injury. Thirty-six
male C57BL/6 mice (approximately 8 weeks of age and
weighing approximately 22–24 g) were randomly divided
into one of three groups: sham controls (n = 12), vehicletreated (n = 13), and 0-1966 treatment (n = 11). The CB2R agonist 0-1966 (0-1966A) is an analog of bicyclic resorcinols
(dimethoxy-resorcinol-dimethylheptyl), a chemical compound structurally similar to cannabidiol, as described by
Wiley and associates (2002). This particular analog demonstrated superior CB2R selectivity (225-fold) and a high binding
affinity for the CB2R (Ki = 22.5 nM); it was also shown to have
poor affinity for CB1R (Wiley et al., 2002). Three naı̈ve mice
that did not receive surgery or treatment were also included.
Controlled cortical impact (CCI), a well-described model for
creating lesions in rodents that are histopathologically similar
to human TBI, was used to create a traumatic injury in vehicleand 0-1966–treated mice. Sham controls received a craniotomy without TBI. 0-1966 (BTG Pharmaceuticals, Inc., London,
U.K.) and vehicle treatments were injected intraperitoneally at
1 and 24 h post- injury (5 mg/kg doses and a volume of
0.1 mL/10 g body weight; Zhang et al., 2009a). Our treatment
paradigm in the present study was based on dosing and time
of administration studies conducted in our models of ischemic
brain and traumatic spinal cord injury (Baty et al., 2008;
Zhang et al., 2009a). The 0-1966 was dissolved in a pure
ethanol:emulphor:saline mixture (1:1:18). Vehicle groups received the same mixture without the cannabinoid agent. All
mice were allowed to wake up from anesthesia and kept in
separate cages post-operatively with unrestricted food and
water. The animals were euthanized with a lethal dose of
sodium pentobarbital for post-mortem histological analysis.
A goal of this study was to examine the effects of a CB2R
agonist on cerebral edema and neurogenic inflammation.
Therefore, a 48-h post-injury time point was chosen for histological assessments, since this is when cerebral edema has
been shown to peak after CCI injury, with subsequent resolution of edema between 4 and 7 days after injury (Baskaya
et al., 2000; Elliott et al., 2008b).
Traumatic brain injury
TBI was produced using a CCI injury model as described
previously by our laboratory (Elliott et al., 2007, 2008b, 2009c),
and modified for mice (Onyszchuk et al., 2007; Saatman et al.,
2006). The mice were anesthetized with isoflurane (5%
induction and 2% maintenance). To ensure aseptic technique,
the heads were shaved using electric clippers, and povidoneiodine and alcohol were applied prior to incision. Thermistors
were implanted into the temporalis muscle and rectum in
order to monitor and maintain brain and core temperatures at
37 – 0.5C. The head was fixed in a stereotaxic frame, and a
high-speed drill was used to create a right-sided 4-mm craniotomy centered between the bregma and the lambda, thus
exposing the sensorimotor cortex. Care was taken to leave the
dura intact and the bone flap was removed. TBI was produced
using an electromagnetic stereotaxic impactor with a 3-mm-
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diameter rounded aluminum tip. TBI was produced using the
predetermined parameters of 1.0 mm depth, 3.0 m/sec velocity, and 100 msec contact time. Following injury, the bone
flap was replaced, sealed with bone wax, and the skin was
sutured closed with 6-0 black silk sutures.
Behavioral testing
Behavioral tests were performed on 7 sham controls, 10
vehicle-treated, 10 0-1966-treated, and 3 naı̈ve mice that did
not receive surgery or treatment. Naı̈ve behavioral test results
were also collected from the vehicle- and 0-1966–treated mice.
A rotarod test was included to fully evaluate the impact on
locomotion. A Rotamex 4/5 (Columbus Instruments, Columbus, OH) consists of a rotating horizontal cylinder (7 cm
diameter) divided into 9.5-cm-wide lanes. The mouse was
placed on the cylinder in a direction that required forward
locomotion to avoid falling. Gradual acceleration occurs from
a speed of 12–35 rpm, and the latencies to fall are detected by a
photobeam circuit over three trials. Results were reported as
mean percentage of baseline latencies – standard error of the
mean (SEM) to account for individual baseline differences in
rotarod performance.
A cylinder test was used to test forelimb motor function as
described by Onyszchuk and colleagues (Baskin et al., 2003;
Onyszchuk et al., 2007). The apparatus consisted of a 10-cmdiameter clear acrylic glass cylinder. Forelimb usage was
observed for two 5-min trials for up to 20 rears per trial. The
number of forelimb placements on the cylinder wall using
both left and right (B), right only (R), or left only (L) forelimbs
was recorded. The results are reported as mean percentage of
baseline usage of the affected (left) forelimb – SEM. Any animals showing right-handedness during baseline testing were
excluded from this test, as an injury to the right cortex in righthanded animals would not cause a change in the left forelimb
use.
Open-field testing was used to assess the activity level for
natural exploratory behavior, and was conducted in a manner
similar to that reported by Wagner and co-workers (Wagner
et al., 2007). The mice were placed in the center of a large (50cm-diameter) acrylic glass box equipped for video monitoring. The number of rears in a 5-min observation period for 2
trials was recorded, and results were reported as the mean
number of rears – SEM.
Cerebral edema measurement
Cerebral edema was evaluated using the wet-dry weight
technique in 7 sham controls, 6 vehicle-treated, and 4 0-1966–
treated mice, using methods described previously by our laboratory (Elliott et al., 2007, 2008b; Okiyama et al., 2007). Briefly,
after administration of a lethal dose of sodium pentobarbital,
the brains were quickly removed and cut using a razor blade.
One 4-mm coronal section that included the traumatic lesion
was collected. Each section was immediately divided into left
and right hemispheres at the midline. The left and right
hemispheres were sectioned on a frozen glass plate into a
cortical region with subcortical regions discarded. The tissue
sections were rapidly transferred onto pre-weighed 2.5-cm2
aluminum foil squares and placed in a humid chamber to
prevent water loss. A wet weight was measured for each tissue
sample and foil square. Subsequently, the tissue and foil were
dried at 100C for 48 h, and reweighed for the dry weight. The
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percentage of brain water was calculated as the difference between the wet and dry weights divided by the wet weight.
Results are reported as mean percent cerebral edema – SEM.
Immunohistochemistry
Five sham control, 7 vehicle-treated, and 7 0-1966–treated
mice were used for immunohistochemistry. The mice were
administered a lethal dose of sodium pentobarbital (120 mg/
kg IP), and underwent cardiac perfusion with heparinized
saline, followed by 4% paraformaldehyde. The brains were
quickly removed and post-fixed in 4% paraformaldehyde for
2 h, at which point they were transferred to 30% sucrose solution until sinking for cryoprotection. The brains were sectioned coronally with a cryostat at - 24C (10 lm thick, 1:10
series, 100 microns between series), mounted, and air dried
overnight, then stored at - 20C until staining. Substance P
immunostaining was performed using a rabbit anti-substance
P primary antibody (cat. no. AB1566; Millipore, Billerica,
MA). Macrophages/microglia were stained with rabbitspecific protein ionizing calcium-binding adaptor molecule
(Iba1) primary antibody (1: 250, cat. no. 019-19741; Wako
Chemicals USA, Inc., Richmond, VA). Substance P and Iba1
were visualized with DyLight 549- and 488-conjugated AffiniPure goat anti-rabbit IgG secondary antibodies ( Jackson
ImmunoResearch, West Grove, PA). 4,6-Diamino-2-phenylindole (DAPI) was used as a nuclear counter-stain for cell
counting (cat. no. D3571; Invitrogen, Carlsbad, CA). Negative
control staining was performed by omitting the primary antibody or by omitting the secondary antibody. Brain tissues
were analyzed using a fluorescence microscope with an x,y
motorized stage. This microscope was interfaced with a
computerized quantification system (BIOQUANT Image,
Nashville, TN), and images were captured using a Retiga EXI
cooled camera (QImaging, Surrey, B.C., Canada). To evaluate
differences in substance P immunostaining, semi-quantitative
methods were used to count the number of sites of substance P immunostaining in the ipsilateral hemisphere around
the injury core. Only punctate substance P staining visualized
perivascularly and within the parenchyma proximal to cerebral blood vessels were counted. Using an independent random start, the number of substance P sites were counted
under a 40 · objective (700 · magnification) in three square
regions of interest (ROIs) in three sections per brain, and reported as mean – SEM. For microglial/macrophage activation, morphological examination and the number of Iba1positive cells were counted using an independent random
sampling approach (Elliott et al., 2010; Mouton, 2002). Ipsilateral and contralateral ROIs were randomly selected in areas
surrounding the necrotic zone of the injury epicenter using
three rectangular boxes (640 · 480 lm) with the BIOQUANT
image analysis system under a 20 · objective (350 · magnification). The number of Iba1-positive cells in three ROIs were
counted per section per hemisphere in three adjacent sections
per brain through the injury core. To avoid bias in estimating
the mean number of Iba1-positive cells, only cells in which the
nucleus (DAPI counter-stained) was visible were counted. All
cell counts were performed in a blinded manner.
Statistical analysis
Single-factor group comparisons (naı̈ve, sham, TBI + vehicle, and TBI + 0-1966) were made using one-way analysis of
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variance (ANOVA), followed by Tukey’s post-hoc comparisons. Significance levels were set at p < 0.05 for all statistical
analyses, and results are reported as the mean and SEM. All
data were analyzed using the GraphPad Prism 5 statistical
program.
Results
Behavioral outcome
TBI produced significant deficits in locomotor and exploratory behavior (Fig. 1). Sham mice (craniotomy only) did not
show any significant functional differences compared to naı̈ve
mice on any behavioral tests. Locomotor performance and
exploratory behavior were significantly improved in mice
receiving 0-1966 (CB2R agonist) compared to vehicle-treated
mice at 48 h post-TBI (Fig. 1). Rotarod latencies for TBI mice
treated with vehicle were significantly reduced compared to
sham mice ( p < 0.001), indicating substantial deficits in balance and coordination (Fig. 1A). Treatment with 0-1966
improved performance on the rotarod compared to vehicletreated mice ( p < 0.01). Deficits in usage of the affected forelimb were significantly greater in TBI mice treated with
vehicle compared to sham mice ( p < 0.001), while treatment
with 0-1966 improved usage of the affected forelimb after TBI
compared to vehicle alone ( p < 0.01; Fig. 1B). Open-field exploratory activity (rearing) was significantly reduced in TBI
mice treated with vehicle compared to sham mice ( p < 0.001;
Fig. 1C). Treatment with 0-1966 promoted normal exploratory
activity after TBI compared to vehicle-treated mice ( p < 0.01).
Edema and substance P
Cerebral edema (percent water content) was significantly
greater in TBI mice treated with vehicle compared to sham
animals ( p < 0.001; Fig. 2A). Treatment with 0-1966 significantly reduced edema compared to vehicle-treated mice
( p < 0.01). Although substance P immunoreactivity increased
throughout several areas of the brain after injury, including
but not limited to the cerebral cortex, thalamus, and spinal
trigeminal tract in the brainstem, assessment of substance P
was limited to the cerebral cortex (Figs. 2B, 3, and 4). The
number of perivascular/parenchymal substance P-immunoreactive areas within the ipsilateral cerebral cortex was significantly greater in TBI mice treated with vehicle compared
to sham animals ( p < 0.01), while 0-1966 attenuated substance
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P immunoreactive product compared to vehicle alone
( p < 0.05; Fig. 2B and 3).
Macrophage/microglial activation
The number of Iba1-positive cells and activated macrophage/microglia morphology in the injured hemisphere was
significantly greater for TBI mice treated with vehicle compared to sham animals ( p < 0.001; Figs. 5–7). Treatment with
0-1966 significantly reduced the number of ipsilateral activated macrophages/microglia compared to vehicle-treated
mice ( p < 0.001; Fig. 5). Microscopic examination under low
magnification revealed TBI mice treated with vehicle had increased Iba1-immunoreactive product, number of Iba1-positive cells, tissue swelling, and a greater area of tissue damage
(necrotic zone; Fig. 6). Examination under high magnification
revealed that vehicle-alone brains had more cells showing an
activated morphology characterized by an amoeboid shape
with retracted/shortened processes compared to the thinner,
highly-branched processes seen in the control and 0-1966
brains (Fig. 7). At the medial border of the craniotomy, injured
and sham animal cerebral cortices demonstrated minimal
microglial activation in the craniotomized hemisphere; however, there was no significant difference in macrophage/microglia activation between the contralateral hemisphere and
sham brains.
Discussion
The present study shows that CB2R activation results in
improved locomotor function and exploratory activity in a
murine model of TBI. Furthermore, these improvements in
functional outcome are associated with a reduction in cerebral
edema, reduced perivascular substance P immunoreactivity,
and diminished macrophage/microglial activation in the injured brains at 48 h post-injury.
Effects on neurogenic inflammation: Cerebral edema
and neurotransmitter and cellular responses
Our results are consistent with those reported by Donkin
and colleagues, indicating that TBI leads to substantial increases in perivascular substance P immunoreactivity (Donkin
et al., 2009). Perivascular substance P immunoreactivity was
found to clearly outline the cerebral vasculature, while also
appearing in its unbound punctate form within the paren-

FIG. 1. Effects of the cannabinoid-2 receptor (CB2R) agonist 0-1966 on rotarod, forelimb cylinder, and open-field exploration
tests at 48 h after traumatic brain injury (TBI). Treatment with 0-1966 improved performance on the rotarod (A) where (a)
represents a significant difference between vehicle-treated mice and naı̈ve and sham controls ( p < 0.001 and p < 0.01, respectively), and (b) represents a significant difference between mice receiving 0-1966 and vehicle9treated mice ( p < 0.01).
Treatment with 0-1966 increased the usage of the affected forelimb (B), where (a) represents a significant difference between
vehicle-treated and sham mice ( p < 0.001), and (b) represents a significant difference between mice receiving 0-1966 and
vehicle ( p < 0.01). Treatment with 0-1966 promoted exploratory/rearing activity (C), where (a) represents a significant difference between vehicle- and sham-treated mice ( p < 0.001), and (b) represents a significant difference between mice receiving
0-1966 and vehicle-treated mice ( p < 0.01; naı̈ve n = 20, sham n = 7, vehicle n = 10, and 0-1966 n = 10).
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FIG. 2. Effects of the cannabinoid-2 receptor agonist 0-1966 on cortical edema (A), and perivascular/parenchymal substance
P immunoreactive product (B), at 48 h after traumatic brain injury (TBI). Percent water content was significantly greater in the
vehicle-treated mice compared to sham animals ( p < 0.001; a). Figure 2A shows that treatment with 0-1966 significantly
reduced the percent water content compared to vehicle-treated mice ( p < 0.01; b). Results are expressed as mean percent
water content – standard error of the mean [SEM]; sham n = 7, vehicle n = 6, and 0-1966 n = 4). Figure 2B shows that TBI
significantly increased the number of perivascular/parenchymal substance P–immunoreactive areas within the ipsilateral
cerebral cortex in vehicle-treated mice compared to sham animals ( p < 0.01; a), that was attenuated in the 0-1966-treated
group ( p < 0.05; b; results are expressed as mean number of immunoreactive areas – SEM; n = 4/group).
chyma. Substance P also appeared bound to plasma membranes of cells morphologically identified as neurons and astrocytes; however, microglia could not be ruled out. Numerous
studies have shown that activated sensory fibers release substance P perivascularly, which then subsequently binds to local
glial and neuronal cells (Black, 2002; Donkin et al., 2009; Marriott and Bost, 1998; Severini et al., 2002). Substance P is a potent
vasogenic neuropeptide from the tachykinin family that is released as a result of mechanical, chemical, and electrical stimulation of sensory neuron C-fibers (Black, 2002; Donkin et al.,
2007; Severini et al., 2002). Cerebral and meningeal blood vessels receive a dense supply of sensory afferents that release
substance P when stimulated, whereby changes in blood flow
and intracranial pressure promote its release. Previously, in a
model of chronic peripheral nerve injury, our laboratory
showed substance P to be increased in the parenchyma and
microvasculature of the dorsal horn of the spinal cord following repeated mechanical trauma (Elliott et al., 2008a, 2009a,
2009b; Elliott et al., 2010). Although multiple tachykinins, such
as calcitonin-gene related peptide, play a role in the formation
of cerebral edema, substance P is clearly the primary contributor to the development of increased vascular permeability and

plasma extravasation. Furthermore, substance P alters osmotic
gradients and has been implicated in mediating transient
blood–brain barrier disruption after TBI (Donkin et al., 2009).
There is a wealth of evidence to suggest that substance P
promotes the inflammatory response through additional
pathways. For instance, there is a significant amount of data
implicating substance P as a primary mediator of gliosis. The
importance of substance P in regulating gliosis in the injured
CNS by mediating microglial and astrocyte activation and the
release of proinflammatory mediators such as cytokines,
prostaglandins, thromboxane B2, and superoxide ions, cannot
be overlooked (Black, 2002; Donkin et al., 2007; Palma et al.,
1997). Substance P receptors are found on non-neuronal cells,
including astrocytes, lymphocytes, leukocytes, macrophages,
and mast cells. Substance P binding can stimulate these cells
to produce proinflammatory cytokines such as IL-1, IL-6, and
TNF-a (Black, 2002; Lin, 1995; Marriott and Bost, 1998). Substance P has also been shown to downregulate the synthesis
of transforming growth factor (TGF), a polypeptide with
anti-inflammatory properties (Marriott and Bost, 1998). TGF
anti-inflammatory actions are mediated by inhibiting monocyte-derived phagocytes and lymphocytes. Furthermore,

FIG. 3. Micrographs showing substance P immunofluorescence surrounding cerebral blood vessels with longitudinal (A–
C), and transverse (D–F) orientations. Minimal perivascular staining is seen in the brains of sham mice (A and D). Traumatic
brain injury (TBI) mice treated with vehicle (B and E) have substantial perivascular substance P immunostaining, while TBI
mice treated with the cannabinoid-2 receptor agonist 0-1966 show a reduction in perivascular substance P immunostaining
(C and F; scale bar = 100 lm; arrows indicate blood vessels).
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FIG. 4. Micrographs showing substance P immunofluorescence within the brainstem spinal trigeminal tract (spV), which
appears to be mostly bound to axons or dendrites, with very little staining of neuronal cell bodies. Negligible staining was
found in a normal control brain (A). Substance P immunostaining was found in the contralateral (B) and ipsilateral hemispheres (C and D), with greater immunostaining seen ipsilateral to the injury. Images A–C were captured with a 20 ·
objective, and image D with a 60 · objective (scale bar = 50 lm in A–C, and 10 lm in D).

degradation of substance P is a slow process, which allows for
a prolonged presence of the neurotransmitter (Severini et al.,
2002). Therefore, the contribution of substance P to gliosis and
inflammatory cascades may prolong and exacerbate secondary damage after TBI.
CB2R modulation
Currently there is a paucity of pre-clinical data regarding
endocannabinoid-mediated modulation of the post-TBI in-

flammatory response. Our work represents the first study
of selective CB2R modulation in TBI. Recent recognition of
the immunomodulatory properties of the CB2R has led to
increasing focus on this receptor as a therapeutic target
in many models of neuronal injury and neurodegenerative
disease. Growing evidence supports the theory that CB2R
agonists modulate microglial activity such as chemotaxis
and production of proinflammatory cytokines (Cabral et al.,
2008; Cabral and Griffin-Thomas, 2009). Microglia CB2R
expression is negligible at rest and highest during primed

FIG. 5. Effects of the cannabinoid-2 receptor agonist 0-1966 on the number of peri-lesional macrophage/microglia cells at
48 h after traumatic brain injury (TBI). The number of macrophages/microglia was significantly greater in the vehicle-treated
mice compared to sham animals ( p < 0.001; a). Treatment with 0-1966 significantly reduced the number of macrophages/
microglia compared to vehicle-treated mice ( p < 0.001; b). Results are expressed as mean ionizing calcium-binding adaptor
molecule (Iba1)-positive cells/mm3 – standard error of the mean; sham n = 5, vehicle n = 7, and 0-1966 n = 7).
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FIG. 6. Low-magnification (10 · objective) micrograph shows traumatic brain injury (TBI) brains for vehicle-treated animals
(A), and animals receiving 0-1966 (B). The vehicle-treated brain (A) has increased ionizing calcium-binding adaptor molecule
(Iba1)-immunoreactive product and more of Iba1-positive cells, tissue swelling, and a greater area of tissue damage (necrotic
zone), delineated by the white brackets, compared to the mice receiving the cannabinoid-2 receptor agonist 0-1966 (B; scale
bar = 100 micrometers).
and activated states such as those occurring after injury,
indicating its relevance in neuroimmune function (Cabral
et al., 2008). It is hypothesized that the role of microglial
CB2R activity is predominantly anti-inflammatory (Carrier
et al., 2005). Our finding that a CB2R agonist reduced edema
and substance P immunoreactivity, as well as dampening
the immune cell response to TBI, supports this hypothesis
and the anti-inflammatory effects we have reported in our
other CNS injury models. Previously, using real-time RTPCR, our laboratory found increased expression of the
CB2R in a model of traumatic spinal cord injury (Baty et al.,
2008). In the same study, we showed that treatment with
the CB2R agonist reduced TNF-a mRNA expression. Our
laboratory also found that CB2R activation reduced white
blood cell rolling and adhesion, adhesion molecule expression, immune cell infiltration, and macrophage activation, in a model of cerebral ischemia (Zhang et al., 2007,
2009a, 2009b). CB2R activation has also been shown to
decrease the activity of antigen-presenting cells, and to
downregulate cytokine (IFN-c and TNF-a) production following inflammatory stimuli (Berdyshev, 2000; Klein
and Cabral, 2006; Lombard et al., 2007; Walter and Stella,
2004).

Evidence that microglial CB2R activity is predominantly
anti-inflammatory is also suggested by results obtained using
a non-selective CBR agonist, 2-arachidonoyl glycerol (2-AG).
In a study by Panikashvili and associates, the cannabinoid 2AG, which has both CB1R- and CB2R-mediated neuroprotection following head injury, was associated with inhibition
of NF-jB, TNF-a, IL-1B, and IL-6, as well as attenuated blood–
brain barrier damage (Panikashvili et al., 2005, 2006). In an
in vitro study, 2-AG reduced macrophage-derived TNF-a and
reactive oxygen species after LPS stimulation (Gallily et al.,
2000). Studies also showed that 2-AG elicited neuroprotection
after closed head injury, which was reversed by a CB1R antagonist, while CB1R-knockout mice showed poorer outcomes from TBI. (Panikashvili et al., 2001, 2005, 2006).
Investigators acknowledge the non-selectivity of high dosages of CB1R antagonists, and the fact that CB1R-knockout
mice appear to be neurologically compromised prior to injury
may confound findings. In addition, it has been hypothesized
that 2-AG exerts vasorelaxant actions that may be important
for regulating cerebrovascular function in the injured brain
(Chen et al., 2000). Chen and associates reported that 2-AG
modulates human brain capillary and microvascular responses
to the potent vasoconstrictor endothelin-1, with implications

FIG. 7. High-magnification (60 · objective) micrograph shows ionizing calcium-binding adaptor molecule (Iba1)-positive
macrophages/microglia, and 4,6-diamino-2-phenylindole (DAPI)-immunofluorescent cells in uninjured animals (A), vehicletreated animals (B), and animals receiving the cannabinoid-2 receptor agonist 0-1966 (C). The vehicle-treated brain has a
greater number of cells showing an activated morphology, characterized by an amoeboid shape with retracted/shortened
processes (arrows in B), compared to the highly-branched processes in the control animals (A) and animals receiving 0-1966
(arrowhead in C).
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for a CB1R-mediated mechanism (Chen et al., 2000). Although
studies indicate that the CB1R may have neuroprotective
mechanisms after TBI, the involvement of the CB2R and other
receptors yet to be discovered cannot be excluded by these
studies. In sum, our results and those of others provide evidence that modulation of the macrophage/microglial response to TBI is a potential therapeutic strategy (Bye et al.,
2007; Shein et al., 2008).
Future implications
At present, the mechanisms by which cannabinoids participate in neuroprotection following TBI are poorly understood. Hypothermia, anti-excitotoxicity, reduced calcium
influx, anti-inflammatory and antioxidant activity, inhibited
endothelin-1 vasoconstriction, and blood–brain barrier protection, have all been proposed as potential mechanisms of
this protection (van der Stelt et al., 2002). The prospect that
endocannabinoids may work via multiple mechanisms may
be comparable to current therapeutic compounds used in
clinical trials like progesterone. Clearly, additional exploration into the role of the endocannabinoid system in the
modulation of the post-TBI inflammatory response is needed.
Additionally, further studies are needed to determine whether the immunomodulatory effects of CB2R activation lead to
lasting neuroprotective effects and improvements in behavioral outcome.
Conclusions
In conclusion, our results indicate that the effects of a
selective CB2R agonist, 0-1966, on neuroinflammatory responses, including cerebral edema, substance P immunoexpression, and macrophage/microglial activation, contribute
to recovery of acute deficits in motor function and exploratory activity. These results demonstrate the importance of
immune-endocannabinoid system interactions in the traumatized brain, along with the therapeutic actions of selective
modulation of the CB2R.
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